Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated January 4, 2022, reports on a definitive agreement entered into on December 29, 2021, for a registered direct offering of American Depositary Shares (ADSs). The offering was led by existing investors, including the Company's Chairman, Dr. Ray Prudo.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6 million.
- Shares Issued: 4,311,019 ADSs at a price of $1.40 per ADS.
- Warrants Issued to Investors: 2,155,507 warrants exercisable at $1.65 per ADS, expiring five years from issuance.
- Placement Agent Fees: 8% cash fee of the aggregate purchase price, up to $50,000 in expense reimbursement, a $10,000 non-accountable expense allowance, and warrants equal to 4% of ADSs sold (exercisable at $1.75 per ADS).
- Expected Closing Date: On or about January 4, 2022.
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period, as it focuses solely on the capital raise transaction.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new ADSs and warrants. The transaction increases the Company's cash liquidity by approximately $6 million, subject to closing conditions.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the proceeds to fund operations and advance its product candidates, specifically nomacopan.
Risks and Contingencies:
- The closing of the offering is subject to customary conditions; failure to satisfy these may prevent the offering from closing.
- Forward-looking statements regarding the offering and proceeds are subject to significant risks, including the need for additional capital, uncertainties in cash flows, and the ability to continue as a going concern.
- Operational risks include delays in regulatory approvals for nomacopan, clinical trial uncertainties, patient enrollment difficulties, and manufacturing dependencies.
- Market risks include competition, potential side effects, and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Confirm the actual closing date and final gross proceeds received.
- Verify the updated share count and dilution impact on existing shareholders.
- Review the Company's most recent Form 20-F for detailed cash burn rates and runway analysis.
- Monitor progress on regulatory approvals and clinical trial results for nomacopan.
- Assess the Company's ability to secure additional capital if the $6 million is insufficient to reach commercial milestones.